> ## Content Index
> Fetch the complete content index at: https://nexi.fund/llms.txt
> Use this file to discover other available public pages before exploring further.

# Seven Inoperable Pancreatic Tumors Became Operable. The Tool Was Laser Light
- URL: https://nexi.fund/impact-biotech-padeliporfin-pdac-phase1-2026/
- Published: 2026-10-27T19:30:24.000Z
- Updated: 2026-10-27T19:30:24.000Z
- Description: ImPact Biotech's padeliporfin VTP cuts off a pancreatic tumour's blood supply from inside its feeding artery. Nine of 12 patients in a Phase 1 dose-escalation study reached surgery, and more than half of the resected tumours had clear margins. The trial is small, unblinded and years from a filing.
- Author: Nexi.fund Labs
- Tags: Biotech & Health, #mode-1, #hook-paradox, #track-E, #layout-signal-grid, #brand-heavy

Seven people whose pancreatic tumours had wrapped themselves around the arteries feeding their gut were told surgery was not an option. They went to the operating room anyway. The sequence that got them there was strange by oncology standards: an intravenous photosensitiser, a balloon catheter threaded into the coeliac or superior mesenteric artery, ten minutes of 753-nanometre laser light, two weeks of waiting, then a Whipple or a distal pancreatectomy.

ImPact Biotech published the numbers on 23 October. Of 12 patients treated in the dose-escalation part of its Phase 1 pancreatic trial, nine had been resected or scheduled for surgery. More than 55% of the resected patients had pathology-confirmed negative margins. The company reports no major safety concerns across all three light-dose cohorts.

Twelve patients is a small number. It is an unusual number to be discussing in the same sentence as the word resection.

---

## What the balloon does inside the artery

Padeliporfin is a photosensitiser, not a cytotoxin. It sits inert in the bloodstream until light of the right wavelength reaches it. ImPact gives a fixed 4 mg/kg dose, then threads a dilatation balloon into the artery that feeds the tumour: the coeliac trunk, the common hepatic artery, or the superior mesenteric artery, depending on where the mass sits.

The balloon inflates and stops blood flow. A fibre inside it delivers light for ten minutes, split into two five-minute increments at 200, 400 or 600 mW/cm depending on the cohort. The light triggers a photochemical reaction in the vessel wall that dismantles the tumour's blood supply. Tissue downstream dies. The mass pulls away from the artery it was encasing.

Surgeons wait two weeks before going in. At UCI Health, one of two US sites running the trial, six patients have been treated. Four had residual tumour removed. Three of those four had no cancer cells at the surgical margins.

75% resected or scheduled 

#### Resection rate in Phase 1 Part A

Nine of 12 patients with Stage III locally advanced pancreatic cancer reached surgery after padeliporfin VTP. · *ImPact Biotech, October 2026*

## The rate moved with the light dose

ImPact has now reported the same trial three times, and the number has climbed at each step. In April, at the lowest light dose of 200 mW/cm, two of three evaluable patients reached surgery. In May, across the first two dose levels, five of seven did. By October, across all three cohorts, nine of twelve had been resected or booked.

| Readout                           | Light-dose cohorts     | Resected or scheduled | R0 margins             |
| --------------------------------- | ---------------------- | --------------------- | ---------------------- |
| **SIR, April 2026**               | 200 mW/cm              | 2 of 3 (66%)          | ◆ not reported         |
| **ASCO, May 2026**                | 200 and 400 mW/cm      | 5 of 7 (71%)          | ◆ not reported         |
| **Company release, October 2026** | 200, 400 and 600 mW/cm | 9 of 12 (75%)         | ✔ over 55% of resected |

Padeliporfin VTP in locally advanced PDAC, NCT05919238\. Denominator grows as cohorts complete.

Read the table with care. The denominators accumulate; they are not randomised groups. The October figure counts patients scheduled for surgery alongside patients who already had it. The R0 rate applies only to the resected subset.

What the table does show is a dose-response that held at the highest light level. Dose-escalation studies exist to find the point where toxicity appears. ImPact says it did not find it: no serious treatment-related adverse events, no dose-limiting toxicities, and no arterial injury, thrombosis or ischaemia reported across the cohorts.

## Surgery is the only cure, and most patients never reach it

Pancreatic ductal adenocarcinoma is the third-leading cause of cancer death in the United States. Five-year survival sits near 10%, the worst of any solid tumour. Roughly half of patients present with disease confined to the pancreas. Two-thirds of that half are inoperable because the tumour has grown into the vessels a surgeon would have to cut and rebuild.

For them the alternatives are chemotherapy and radiation, which downstage a minority, or palliative care. UCI's principal investigator frames the stakes without decoration.

> We use the light-sensitive drug padeliporfin to destroy pancreatic tumors encasing major arteries in the abdomen — once the vessels are clear of tumors, patients can undergo what can be a lifesaving surgery.— Nadine Abi-Jaoudeh, interventional radiologist, UCI Health

Abi-Jaoudeh makes a sharper point elsewhere in UCI's September release. Patients with localised but inoperable pancreatic cancer have survival rates about as poor as patients whose disease has already spread. Resectability is not a proxy for survival here. It is the gate everything else sits behind.

## Three days in the dark

The treatment carries an obvious cost. Padeliporfin leaves the whole body photosensitive for days. Patients spend three days in a darkened room after infusion, because ordinary light can burn skin and eyes. That constraint has kept the technique limited to small, well-defined volumes instead of large radiation-style fields.

The procedure also needs an interventional radiology suite, a trained operator, and a tumour a catheter can actually reach. It is a session, a wait, then major surgery in patients who were already marginal candidates for anaesthesia.

The evidence base is thin in the ways early oncology data usually is. The trial is open-label, non-randomised and single-arm. Investigators know which dose each patient received. Resectability is a surgeon's judgement, and the line between borderline resectable and unresectable shifts between centres. Twelve patients across three cohorts cannot separate a drug effect from patient selection. There is no control arm receiving chemotherapy downstaging.

⚠️

**Three results that would weaken the signal**  
  
A Part B resection rate below 70% as less-selected patients enrol.  
  
An R0 rate that falls once more centres apply their own pathology thresholds.  
  
Any safety event at 600 mW/cm that the 3+3 design was too small to catch. 

None of that makes the October result meaningless. It makes it a mechanism with a hypothesis attached, which is more than most Phase 1 oncology press releases carry.

## Why twelve patients is the right size for this question

The trial is a 3+3 dose escalation, the oldest design in oncology. Three patients enter a cohort. If none has a dose-limiting toxicity, the next cohort gets more light. If one does, three more are added. The maximum tolerated dose is the level where fewer than 33% of evaluable patients hit a DLT, and that level becomes the recommended Phase 2 dose.

That design answers a safety question efficiently in a population whose alternative is palliative care. It cannot answer an efficacy question, and the registry says so: resectability and downstaging sit in exploratory endpoints, measured as the share of patients who move from unresectable to borderline or resectable after treatment.

Part B then opens at the selected light dose with a larger expansion cohort. Estimated enrolment is 30 patients across two US sites. Part A began in May 2024 and primary completion is pencilled in for August 2027\. Surgery follows VTP by roughly two weeks, so pathology is read on tissue that has had time to respond and then time to be removed.

The October number is a floor for what Part B can show. Nine of twelve came from a cohort built to test light intensity, at centres that had already learned the procedure.

## A platform bet priced on urothelial cancer

ImPact is not a pancreatic company. The same drug-device pair is furthest along in low-grade upper tract urothelial carcinoma, where the Phase 3 ENLIGHTED trial finished treating all required patients in September 2026\. The company plans an NDA in 2027 and has said it will lean on non-clinical modules from an earlier prostate filing.

That prostate history matters for the mechanism. Padeliporfin is the active substance in Tookad, authorised in the European Union since 2017 for low-risk prostate cancer. The molecule has been through a regulator before, in a different organ. Pancreatic cancer is the harder test: worse anatomy, sicker patients, and an endpoint of surgery rather than tissue ablation.

Pancreatic is one of three expansion bets. ImPact lists non-small cell lung cancer and high-grade urothelial cancer alongside it, and has been explicit about seeking a partner to fund the urothelial commercial build.

> These early clinical observations represent an exciting step forward for ImPact Biotech and reinforce our belief in the potential of Padeliporfin VTP to address some of the most challenging solid tumors.— Barak Palatchi, chief executive, ImPact Biotech

Part B will use the light dose selected from Part A and enrol more patients at the same two US sites. The trial's estimated primary completion is August 2027\. That readout decides the story: same protocol, more patients, and a resection rate that either holds near 75% or does not.

### Will a twelve-patient signal survive Part B?

🔮

**By the end of 2027, ImPact reports Part B resection data and opens FDA discussions on a registrational pancreatic study.**  
  
Probability: 60% — the dose-response held across three successive readouts and the safety profile is clean, but the cohort is small and resectability is a soft endpoint. 

🎯

VTP turned a vascular exclusion into an operable tumour in nine of twelve patients.  
  
The effect rose with light dose while reported toxicity stayed flat.  
  
The three-day photosensitivity window and the single-arm design are what decide whether it scales. 

#### 🟢 Optimistic scenario (25%)

Part B holds above 70% resection with R0 over 60% on a larger cohort.  
  
**Consequence:** the FDA accepts a single-arm registrational design in a population with no surgical alternative, and pancreatic moves ahead of the urothelial filing. 

#### 🟡 Base case (50%)

The resection rate falls into the 50–65% range as less-selected patients enrol and more centres grade resectability.  
  
**Consequence:** ImPact runs a randomised Phase 2 against chemotherapy downstaging before any registrational conversation, pushing the pancreatic timeline past 2029\. 

#### 🔴 Pessimistic scenario (25%)

Toxicity appears at the highest light dose once the cohort widens, or pathology finds viable tumour at the margins in most resected patients.  
  
**Consequence:** the pancreatic programme narrows to a niche salvage indication while the urothelial filing carries the platform. 

[ ImPact Biotech reports Phase 1 Part A results in pancreatic cancer The primary announcement: 9 of 12 patients resected or scheduled, over 55% R0 among resected patients, and a clean safety read across three light-dose cohorts. ImPact Biotech via GlobeNewswire ](https://www.globenewswire.com/news-release/2026/10/23/3387201/0/en/impact-biotech-reports-encouraging-early-clinical-results-from-phase-1-study-of-padeliporfin-vtp-in-pancreatic-cancer-with-seven-previously-unresectable-patients-undergoing-surgica.html?ref=nexi.fund) 

Company-reported, not peer-reviewed. Treat the percentages as exploratory; the trial is still recruiting.

[ NCT05919238: Padeliporfin VTP for unresectable pancreatic adenocarcinoma The registry record behind the numbers: 30-patient Phase 1, 3+3 light-dose escalation at 200, 400 and 600 mW/cm, 4 mg/kg fixed dose, two US sites, primary completion August 2027. ClinicalTrials.gov ](https://clinicaltrials.gov/study/NCT05919238?ref=nexi.fund) 

The protocol is the check on the press release: resectability and downstaging sit in exploratory endpoints, not the primary safety measure.

[ First-in-human laser trial at UCI Health targets inoperable pancreatic tumours The clinical-site view: six patients treated, four resected, three with clear margins, plus the investigators' account of the two-week wait and the dark-room recovery. UCI Health / EurekAlert ](https://www.eurekalert.org/news-releases/1143590?ref=nexi.fund) 

Useful because it predates the company's larger cohort and states the limitation plainly: this is an early clinical report, not a randomised result.